| Species |
Human |
| Protein Construction |
TFPI-2 (Asp23-Lys213)_x000D_
Accession # NP_006519.1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate, the IC50 value is < 5 nM. Test result meets the standard |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
22.9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 30-35 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Tissue factor pathway inhibitor-2 (TFPI-2) has previously been characterized as an endogenous anticoagulant. TFPI-2 is expressed in the vast majority of cells, mainly secreted into the extracellular matrix. Moreover, in sputum from cystic fibrosis patients TFPI-2 C-terminal fragments are generated and found associated with immunoglobulins. Together our data describe a previously unknown host defense mechanism and therapeutic importance of TFPI-2 against invading Gram-negative bacterial pathogens. |
| Synonyms |
TFPI-2; PP5; TFPI2; REF1; TFPI-2REF1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
